LevelJump Announces Q1 2024 Financial Results
LevelJump Healthcare Corp. (TSXV: JUMP) has released its Q1 2024 financial results, highlighting strong revenue growth. Key points include:
- Canadian Teleradiology Services (CTS) revenues reached $4.1 million, a 46% year-over-year increase
- Consolidated net loss of $(501,480)
- Consolidated EBITDA of $97,742
CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues. With the opening of the Yonge Sheppard location, LevelJump anticipates revenues to grow to over $20 million annually, with consistently positive EBITDA. The company uses non-IFRS financial measures like adjusted EBITDA to evaluate operating performance and liquidity.
LevelJump Healthcare Corp. (TSXV: JUMP) ha pubblicato i risultati finanziari del primo trimestre del 2024, evidenziando una forte crescita dei ricavi. I punti chiave includono:
- I ricavi dei Servizi di Teleradiologia Canadese (CTS) hanno raggiunto $4,1 milioni, con un aumento del 46% rispetto all’anno precedente
- Perdita netta consolidata di $(501,480)
- EBITDA consolidato di $97,742
Il CEO Mitch Geisler ha osservato che l'azienda sta monitorando oltre $16 milioni all'anno in ricavi. Con l'apertura della sede di Yonge Sheppard, LevelJump prevede che i ricavi supereranno i $20 milioni all’anno, con un EBITDA sempre positivo. L'azienda utilizza misure finanziarie non-IFRS come l'EBITDA rettificato per valutare le prestazioni operative e la liquidità.
LevelJump Healthcare Corp. (TSXV: JUMP) ha publicado sus resultados financieros del primer trimestre de 2024, destacando un fuerte crecimiento en los ingresos. Los puntos clave incluyen:
- Los ingresos de los Servicios de Teleradiología Canadiense (CTS) alcanzaron $4,1 millones, un aumento del 46% interanual
- Pérdida neta consolidada de $(501,480)
- EBITDA consolidado de $97,742
El CEO Mitch Geisler señaló que la empresa está rastreando más de $16 millones anuales en ingresos. Con la apertura de la ubicación de Yonge Sheppard, LevelJump anticipa que los ingresos crecerán a más de $20 millones anuales, con un EBITDA consistentemente positivo. La empresa utiliza medidas financieras no-IFRS como EBITDA ajustado para evaluar el rendimiento operativo y la liquidez.
LevelJump Healthcare Corp. (TSXV: JUMP)는 2024년 1분기 재무 결과를 발표하며 강력한 매출 증가를 강조했습니다. 주요 내용은 다음과 같습니다:
- 캐나다 원격의료 서비스(CTS) 매출은 $4.1백만에 도달하여 지난해 대비 46% 증가했습니다
- 연결 순손실 $(501,480)
- 연결 EBITDA $97,742
CEO 미치 가이스러는 회사가 이제 연간 $16백만 이상의 매출을 추적하고 있다고 언급했습니다. Yonge Sheppard 지점의 개설로 LevelJump는 연간 $20백만 이상의 매출 성장을 예상하며, 지속적으로 긍정적인 EBITDA를 기록할 것으로 기대하고 있습니다. 회사는 운영 성과와 유동성을 평가하기 위해 조정된 EBITDA와 같은 비-IFRS 재무 지표를 사용합니다.
LevelJump Healthcare Corp. (TSXV: JUMP) a publié ses résultats financiers du premier trimestre 2024, mettant en avant une forte croissance des revenus. Les points clés incluent :
- Les revenus des Services de Téléradiologie Canadiens (CTS) ont atteint $4,1 millions, soit une augmentation de 46 % par rapport à l'année précédente
- Perte nette consolidée de $(501,480)
- EBITDA consolidé de $97,742
Le PDG Mitch Geisler a noté que l'entreprise suit désormais plus de $16 millions par an de revenus. Avec l'ouverture du site de Yonge Sheppard, LevelJump s'attend à ce que les revenus dépassent $20 millions par an, avec un EBITDA toujours positif. L'entreprise utilise des mesures financières non-IFRS comme l'EBITDA ajusté pour évaluer la performance opérationnelle et la liquidité.
LevelJump Healthcare Corp. (TSXV: JUMP) hat die Finanzzahlen für das erste Quartal 2024 veröffentlicht und damit ein starkes Umsatzwachstum hervorgehoben. Die wichtigsten Punkte sind:
- Die Umsätze der Canadian Teleradiology Services (CTS) erreichten $4,1 Millionen, was einem Anstieg von 46% im Jahresvergleich entspricht
- Konsolidierter Nettoverlust von $(501,480)
- Konsolidiertes EBITDA von $97,742
CEO Mitch Geisler stellte fest, dass das Unternehmen nun mehr als $16 Millionen jährlich an Einnahmen verfolgt. Mit der Eröffnung des Standorts Yonge Sheppard erwartet LevelJump, dass die Umsätze auf über $20 Millionen jährlich steigen werden, mit durchgehend positivem EBITDA. Das Unternehmen verwendet nicht-IFRS Finanzkennzahlen wie bereinigtes EBITDA zur Bewertung der operativen Leistung und Liquidität.
- CTS revenues increased by 46% year-over-year to $4.1 million in Q1 2024
- Company is tracking over $16 million in annual revenues
- Anticipated revenue growth to over $20 million annually with the opening of Yonge Sheppard location
- Consolidated EBITDA of $97,742 for Q1 2024
- Consolidated net loss of $(501,480) for Q1 2024
Toronto, Ontario--(Newsfile Corp. - August 29, 2024) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company"), announced today its financial results for the quarter ended March 31, 2024.
Financial and Operational Highlights
- Revenues from Canadian Teleradiology Services, Inc. ("CTS") were
$4.1 million in the first quarter of 2024.
- CTS Year over Year Q1 revenues increased by
46% .
2024 Q1 Financial Results for LevelJump
Consolidated net loss of
$(501,480) for the first quarter of 2024.Consolidated EBITDA of
$97,742 for the first quarter of 2024.
Management Comments
"We had another strong quarter of revenue and are now tracking over
Non-IFRS Financial Measures
This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.
Adjusted EBITDA & Annual Revenue Run Rate
Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.
EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment and finance income.
A reconciliation of adjusted EBITDA to net income (loss) is as follows:
| Three Months ended March 31 | ||||||
| ($ in thousands) | 2024 | 2023 | ||||
| Net income (loss) and comprehensive income (loss) | (502 | ) | (239 | ) | ||
| Add back: | ||||||
| Depreciation and amortization | 310 | 92 | ||||
| Net interest expense | 236 | 56 | ||||
| Taxes | - | 9 | ||||
| Misc and foreign exchange | 53 | (2 | ) | |||
| EBITDA | 97 | (84 | ) | |||
| Add back: | ||||||
| One-time Professional Fees related to Acquisitions | - | 100 | ||||
| Adjusted EBITDA | 97 | 18 | ||||
For further details on the results, please refer to LevelJump's Management, Discussion and Analysis and Consolidated Financial Statements for the Three Months Ended March 31, 2024, which are available on the Company's website (www.leveljumphealthcare.com) and under the Company's profile on SEDAR (www.sedarplus.ca).
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler
Chief Executive Officer
info@leveljumphealthcare.com
647-340-2020
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221496
FAQ
What was LevelJump Healthcare's (JMPHF) revenue for Q1 2024?
How much did LevelJump Healthcare's (JMPHF) revenue grow in Q1 2024 compared to Q1 2023?
What was LevelJump Healthcare's (JMPHF) net income/loss for Q1 2024?
What is LevelJump Healthcare's (JMPHF) projected annual revenue after opening the Yonge Sheppard location?
